ZhenFund

ZhenFund is widely regarded as China’s premier seed fund, with a portfolio that spans well over a thousand companies and a partner network that touches nearly every corner of the Chinese venture ecosystem. The firm operates from Beijing with offices in other major cities and brings substantial early-stage support to visionary AI founders and smart hospital solutions. Healthcare exposure concentrates on AI/ML applications and health IT software.

The thesis is built around the conviction that the seed stage is where the most valuable venture relationships are formed and that a high-volume, high-touch seed program can systematically capture the most ambitious founders coming out of Chinese universities, corporate technology companies, and research institutions. ZhenFund’s healthcare investments fit into this frame when there is a clear technical wedge, an ambitious founding team, and a credible path to building a category-defining company. The portfolio leans technical and tends to favor AI-driven approaches and software platforms over service-heavy or single-vertical plays.

ZhenFund writes pre-seed, seed, and Series A checks generally between $250k and $1M, operating with the flexibility to be the first institutional money in and to follow on into subsequent rounds. Geographically, the focus is China with particular density in companies emerging from the major technology hubs of Beijing, Shanghai, Shenzhen, and Hangzhou. The check size and stage focus mean ZhenFund is comfortable engaging with companies that are still defining their initial commercial path, with diligence calibrated to early-stage uncertainty.

The partnership is one of the more visible in Chinese venture, with partners who are active in the broader entrepreneurial ecosystem and who maintain extensive networks of co-investors, founders, and corporate partners. That ecosystem reach is structurally relevant for portfolio companies, since it accelerates the introductions, hiring, and follow-on financing that early-stage companies need to compress their development timelines.

In working with companies, ZhenFund’s most distinctive value is its ecosystem reach across the Chinese venture and corporate landscape. The firm helps with senior hiring, follow-on round structuring, and connections into Series A and Series B leads at the most active growth-stage funds in China. For healthcare AI founders, the fit is strongest for those with technically ambitious companies and credible founding teams operating from a Chinese base, particularly in AI-driven clinical tools and smart hospital infrastructure. The fit is weaker for companies operating primarily outside China or for those without a clear technical or AI dimension, since the firm’s reputation and network are calibrated to that context. Founders considering ZhenFund should plan for a process anchored in partner conviction and ecosystem fit, with substantive support during the formation period and ongoing access to the firm’s broader network.